In this interview, Crystal Salvans and Enrico Barichello discuss how Aptar Pharma’s 8 mm RNS offers proven compatibility with auto-injectors and high-viscosity biologics. They highlight its role in supporting pharmaceutical companies with reliable, patient-friendly delivery solutions.
As demand for advanced drug delivery rises, the 8 mm RNS helps meet evolving market needs with confidence and efficiency.
Crystal Salvans and Enrico Barichello provide an in-depth look at the evolving landscape of subcutaneous drug delivery, focusing on the increasing demand for patient-friendly solutions that accommodate high-viscosity biologics. Central to the discussion is Aptar Pharma’s 8 mm Rigid Needle Shield (RNS). Aptar Pharma’s 8 mm RNS is designed by leveraging decades of expertise in RNS technology, a market-proven rubber formulation, and a state-of-the-art manufacturing process.
The article highlights the technical compatibility of the 8 mm RNS with Stevanato Group’s syringe platforms, including Alba® and Nexa® and Auto-Injector.
Its unchanged outer shell allows for seamless integration into existing fill-finish lines, preserving machinability and avoiding costly equipment modifications. This makes it an attractive solution for pharmaceutical companies seeking to streamline operations while maintaining high standards of safety, performance, and regulatory compliance.
From a strategic standpoint, the 8 mm RNS supports pharma partners by offering a scalable, reliable solution that meets both patient expectations and manufacturing needs. RNS is compatible with Auto-injector, which enable home based care, which is aligning with the broader industry shift toward personalized medicine and decentralized treatment models.
The article emphasizes the strategic collaboration between Aptar Pharma and Stevanato Group, combining Aptar Pharma’s expertise in elastomeric components and device integration with Stevanato’s advanced glass syringe platforms, Alba® and Nexa®. In a market increasingly shaped by chronic disease prevalence and the shift toward home-based care, this partnership aims to deliver patient-centric solutions that support safe and efficient drug development.